If you liked this article you might like

Buy Merck on Near-Term Weakness
Hep C Business Slow-Down Could Hamper Bristol-Myers' Future
Top 10 Dividend Aristocrats to Buy at a Discount Now
Johnson & Johnson Is Getting Rather Expensive